Retatrutide reduces knee osteoarthritis pain in two phase 3 trials published in NEJM

Ta vnos je prikazan v angleščini, dokler njegov prevod ne bo posodobljen.

The New England Journal of Medicine published TRIUMPH-4 (445 participants) and TRIUMPH-1-OA (574), phase 3 placebo-controlled trials of investigational retatrutide in adults without diabetes who had painful knee osteoarthritis and a body-mass index of at least 27. In TRIUMPH-4, the WOMAC pain score (0 to 10, higher is worse) fell by 3.96 and 3.74 points with the two doses at 68 weeks versus 2.12 with placebo, and body weight fell by 20.0% and 23.7% versus 4.6%. In TRIUMPH-1-OA, the pain score fell by 3.22 to 3.64 points across three doses at 80 weeks versus 1.87 with placebo. Serious adverse events were more common with retatrutide than with placebo in both trials, gastrointestinal events were the most common adverse events, and retatrutide remains unapproved.

Vir

  1. 01Retatrutide Once Weekly in Adults with Knee Osteoarthritis Pain and Obesity(odpre vir v novem zavihku) New England Journal of Medicine via PubMed

Zadevni peptidi

  1. V kliničnih preskušanjihRetatrutideTrojni agonist receptorjev GIP, GLP-1 in glukagona39 Prepovedano (WADA)